BenzingaOctober 13, 2026 at 4:58 AM NY14 Days Ago
Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
